Waymo just took its hands off the wheel in Nashville. The Alphabet-owned company has removed human safety drivers from its test cars, a key step toward launching a full robotaxi service in the city later this year with Lyft. Riders will book through the Waymo app first, with Lyft joining in once the fleet scales. Nashville now joins a growing list of U.S. cities where Waymo is inching closer to turning self-driving tech into an everyday ride. (TechCrunch)

Target is trying to fix what shoppers keep complaining about messy stores, empty shelves and slow lines. The retailer is shifting more money into in-store staffing and training while cutting about 500 roles across distribution centers and regional offices. New CEO Michael Fiddelke wants more hours on the floor and fewer layers of management as he pushes for a turnaround after four flat years of sales. It is a back-to-basics bet on better service driving growth. (CNBC)

UPS is back in labor court. The Teamsters just sued the delivery giant over a new driver buyout plan that would pay workers to walk away for good, arguing it breaks the union’s national contract. The move lands as UPS is already cutting up to 30,000 jobs and closing facilities to shed low margin Amazon volume. Management says it will handle the dispute legally, but for investors, it adds another layer of risk to an already messy cost-cutting story. (Reuters)

YouTube is slicing up its $83/month TV bundle and selling it in cheaper, more focused pieces. The platform just rolled out 10 new YouTube TV packages built around things like sports, news, movies, and kids content, betting that viewers will pay for exactly what they watch instead of everything. Subscriptions are still small next to ads, but with YouTube owning the connected TV screen, Google clearly wants more of that predictable monthly revenue. (Social Media Today)

Novo Nordisk just took the fight over weight-loss copycats to court. The drugmaker is suing Hims & Hers for selling compounded versions of Wegovy, arguing the shortage loophole is closed and the products violate its patents. Hims says it’s standing up for access and personalization, but regulators and Novo aren’t buying it. With as many as 1.5 million Americans on compounded GLP-1s, the outcome could reshape who controls the booming obesity drug market. (CNBC)

💸 Stuck figuring out who to hire, what software to buy, or which agency to trust?
100dollarintros gives you a free expert consult, introduces you to 2–4 vetted companies, and pays you $100 per meeting
→ Get paid to solve your problems

⚡Getting traffic but not enough sales calls?
Smart founders are building high-value newsletters to book consistent sales calls. If you want predictable B2B leads without burning cash on ads
→ Build your audience here

🧲 Want to make more money from your website?
ShowYourWork.Studio builds high-converting websites that help founders go from “we should launch” to “we just got paid” in just 72 hours.
→ See the 72-hour difference here 

🤝 Want to hire better people with less risk?
Go Carpathian sources top-tier global talent from world-class companies, screens them for skill and fit, and hands you candidates who are ready to perform from day one. Check out how they can help you hire smarter, faster, and 70% cheaper than U.S. rates. 
→ Speak to a recruitment specialist